Recent advances in human flavivirus vaccines

Current Opinion in Virology

Volumn 23, Issue , 2017, Pages 95-101

  Scherwitzl, Iris ^a   Mongkolsapaja, Juthathip ^a,b   Screaton, Gavin ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; MESSENGER RNA; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; WEST NILE VACCINE; ZIKA VIRUS VACCINE; VIRUS VACCINE;

ANTIBODY DEPENDENT ENHANCEMENT; ANTIBODY TITER; DENGUE VIRUS; DRUG EFFICACY; HUMAN; PRIORITY JOURNAL; REVIEW; SEROPREVALENCE; WEST NILE VIRUS; ZIKA VIRUS; DENGUE; DRUG DEVELOPMENT; IMMUNOLOGY; ISOLATION AND PURIFICATION; TRENDS; WEST NILE FEVER; ZIKA FEVER;

DENGUE; DENGUE VIRUS; DRUG DISCOVERY; HUMANS; VIRAL VACCINES; WEST NILE FEVER; WEST NILE VIRUS; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 85018752101     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2017.04.002     Document Type: Review

References (77)

1. 1 Gray, T.J., Webb, C.E., A review of the epidemiological and clinical aspects of West Nile virus. Int. J. Gen. Med. 7 (2014), 193–203.
2. 2 CDC: West Nile Virus. https://www.cdc.gov/westnile/statsmaps/index.html, 2016.
3. 3 Bhatt, S., et al. The global distribution and burden of dengue. Nature 496 (2013), 504–507.
4. 4 Yacoub, S., Mongkolsapaya, J., Screaton, G., Recent advances in understanding dengue. F1000Research, 5, 2016.
5. 5 Guzman, M.G., Alvarez, M., Halstead, S.B., Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch. Virol. 158 (2013), 1445–1459.
6. 6• Halstead, S.B., O'Rourke, E.J., Antibody-enhanced dengue virus infection in primate leukocytes. Nature 265 (1977), 739–741 This paper describes antibody dependent enhancement of dengue virus in vivo using rhesus macaques.
7. 7• Mongkolsapaya, J., et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat. Med. 9 (2003), 921–927 This paper describes original antigenic sin in T cell responses to dengue virus infection.
8. 8 Dejnirattisai, W., et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 328 (2010), 745–748.
9. 9 Dejnirattisai, W., et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat. Immunol. 16 (2015), 170–177.
10. 10 Beltramello, M., et al. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8 (2010), 271–283.
11. 11 Dowd, K.A., et al. Combined effects of the structural heterogeneity and dynamics of flaviviruses on antibody recognition. J. Virol. 88 (2014), 11726–11737.
12. 12 Fibriansah, G., et al. Structural changes in dengue virus when exposed to a temperature of 37 °C. J. Virol. 87 (2013), 7585–7592.
13. 13 Zhang, X., et al. Dengue structure differs at the temperatures of its human and mosquito hosts. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 6795–6799.
14. 14 Musso, D., Gubler, D.J., Zika virus. Clin. Microbiol. Rev. 29 (2016), 487–524.
15. 15• Lazear, H.M., Diamond, M.S., Zika virus: new clinical syndromes and its emergence in the western hemisphere. J. Virol. 90 (2016), 4864–4875 This is a comprehensive review of ZIKVs history, vaccine development and antibody response.
16. 16 Mlakar, J., et al. Zika virus associated with microcephaly. N. Engl. J. Med. 374 (2016), 951–958.
17. 17 Cao-Lormeau, V.M., et al. Guillain–Barre syndrome outbreak associated with Zika virus infection in French polynesia: a case-control study. Lancet 387 (2016), 1531–1539.
18. 18 Mukhopadhyay, S., Kuhn, R.J., Rossmann, M.G., A structural perspective of the flavivirus life cycle. Nat. Rev. Microbiol. 3 (2005), 13–22.
19. 19 Beasley, D.W., Barrett, A.D., Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J. Virol. 76 (2002), 13097–13100.
20. 20 Crill, W.D., Roehrig, J.T., Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J. Virol. 75 (2001), 7769–7773.
21. 21 Screaton, G., et al. New insights into the immunopathology and control of dengue virus infection. Nat. Rev. Immunol. 15 (2015), 745–759.
22. 22 Rouvinski, A., et al. Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature 520 (2015), 109–113.
23. 23 De Filette, M., et al. Recent progress in West Nile virus diagnosis and vaccination. Vet. Res., 43, 2012, 16.
24. 24 Diamond, M.S., et al. A critical role for induced IgM in the protection against West Nile virus infection. J. Exp. Med. 198 (2003), 1853–1862.
25. 25 Diamond, M.S., et al. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J. Virol. 77 (2003), 2578–2586.
26. + T cells in control of West Nile virus infection. J. Virol. 78 (2004), 8312–8321.
27. 27 Brien, J.D., Uhrlaub, J.L., Nikolich-Zugich, J., Protective capacity and epitope specificity of CD8(+) T cells responding to lethal West Nile virus infection. Eur. J. Immunol. 37 (2007), 1855–1863.
28. + T cells to vaccine immunity against West Nile encephalitis virus. Vaccine 26 (2008), 2020–2033.
29. + T cells mediate recovery and immunopathology in West Nile virus encephalitis. J. Virol. 77 (2003), 13323–13334.
30. 30 Szretter, K.J., et al. 2′-O methylation of the viral mRNA cap by West Nile virus evades ifit1-dependent and -independent mechanisms of host restriction in vivo. PLoS Pathog., 8, 2012, e1002698.
31. 31 Arroyo, J., et al. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J. Virol. 78 (2004), 12497–12507.
32. 32 Tesh, R.B., et al. Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model. Emerg. Infect. Dis. 8 (2002), 1392–1397.
33. 33 Monath, T.P., et al. A live, attenuated recombinant West Nile virus vaccine. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 6694–6699.
34. 34• Biedenbender, R., et al. Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults. J. Infect. Dis. 203 (2011), 75–84 See Ref. [35•].
35. 35• Dayan, G.H., et al. Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults >/= 50 years of age. Vaccine 30 (2012), 6656–6664 Refs. [34,35] describe the first ever phase II trials of a West Nile virus vaccine, which showed an overall efficacy of over 90% in healthy adults.
36. 36 Pletnev, A.G., et al. Chimeric West Nile/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity. Vaccine 24 (2006), 6392–6404.
37. 37 Pletnev, A.G., et al. West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 3036–3041.
38. 38 Durbin, A.P., et al. The live attenuated chimeric vaccine rWN/DEN4Delta30 is well-tolerated and immunogenic in healthy flavivirus-naive adult volunteers. Vaccine 31 (2013), 5772–5777.
39. 39• Amanna, I.J., Raue, H.P., Slifka, M.K., Development of a new hydrogen peroxide-based vaccine platform. Nat. Med. 18 (2012), 974–979 This article describes a new vaccine platform that uses hydrogen peroxide to inactivate viruses for vaccine production.
40. 40 Pinto, A.K., et al. A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal West Nile virus infection in aged mice. J. Virol. 87 (2013), 1926–1936.
41. 41 Martin, J.E., et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J. Infect. Dis. 196 (2007), 1732–1740.
42. 42 Ledgerwood, J.E., et al. A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J. Infect. Dis. 203 (2011), 1396–1404.
43. 43 Lieberman, M.M., et al. Preparation and immunogenic properties of a recombinant West Nile subunit vaccine. Vaccine 25 (2007), 414–423.
44. 44 Lieberman, M.M., et al. Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeys. Clin. Vaccine Immunol. 16 (2009), 1332–1337.
45. 45 Watts, D.M., et al. Efficacy and durability of a recombinant subunit West Nile vaccine candidate in protecting hamsters from West Nile encephalitis. Vaccine 25 (2007), 2913–2918.
46. 46 Coller BA, Vidya P, Weeks-Levy C, Ogata S: United States Patent Application No. US20120141520 A1: Recombinant Subunit West Nile Virus Vaccine for Protection of Human Subjects, 2012.
47. 47 Guy, B., et al. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 29 (2011), 7229–7241.
48. 48• Capeding, M.R., et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384 (2014), 1358–1365 See Ref. [49•].
49. 49• Villar, L., et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N. Engl. J. Med. 372 (2015), 113–123 Refs. [48,49] describe the first ever phase III trial of a dengue vaccine, which showed an overall efficacy of 66% in children from Latin America and Asian children.
50. 50 Hadinegoro, S.R., et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N. Engl. J. Med. 373 (2015), 1195–1206.
51. 51 SAGE, W.H.O, Summary of the April Meeting of the Strategic Advisory Group of Experts on immunization (SAGE). 2016, WHO, 1–4.
52. 52 Durbin, A.P., et al. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. J. Infect. Dis. 207 (2013), 957–965.
53. 53 Kirkpatrick, B.D., et al. Robust and balanced immune responses to all 4 Dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults. J. Infect. Dis. 212 (2015), 702–710.
54. 54•• Kirkpatrick, B.D., et al. The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model. Sci. Transl. Med., 8, 2016, 330ra36 This article uses a live attenuated dengue vaccine candidate TV003 in a dengue human challenge model to assess the protective efficacy. TV003 induced complete protection against challenge with rDEN2Δ30.
55. 55 Osorio, J.E., et al. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. Lancet Infect. Dis. 14 (2014), 830–838.
56. 56 Rupp, R., et al. Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: a phase 1b randomized study. Vaccine 33 (2015), 6351–6359.
57. 57 George, S.L., et al. Safety and immunogenicity of a live attenuated tetravalent dengue vaccine candidate in flavivirus-naive adults: a randomized, double-blinded phase 1 clinical trial. J. Infect. Dis. 212 (2015), 1032–1041.
58. 58 Sirivichayakul, C., et al. Safety and immunogenicity of a tetravalent dengue vaccine candidate in healthy children and adults in dengue-endemic regions: a randomized, placebo-controlled phase 2 study. J. Infect. Dis. 213 (2016), 1562–1572.
59. 59• Thomas, S.J., Rothman, A.L., Trials and tribulations on the path to developing a dengue vaccine. Vaccine 33:Suppl. 4 (2015), D24–D31 This is a comprehensive review on dengue vaccine development.
60. 60 Coller, B.A., et al. The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine 29 (2011), 7267–7275.
61. 61 Manoff, S.B., et al. Preclinical and clinical development of a dengue recombinant subunit vaccine. Vaccine 33 (2015), 7126–7134.
62. 62 Lim, S.K., et al. Prospects for dengue vaccines for travelers. Clin. Exp. Vaccine Res. 5 (2016), 89–100.
63. 63 Raviprakash, K., et al. Needle-free biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-CSF gene increases immunogenicity and protection from virus challenge in Aotus monkeys. Virology 315 (2003), 345–352.
64. 64 Raviprakash, K., et al. Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF. Virology 290 (2001), 74–82.
65. 65 Beckett, C.G., et al. Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial. Vaccine 29 (2011), 960–968.
66. 66 Raviprakash, K., et al. A dengue DNA vaccine formulated with Vaxfectin(R) is well tolerated: and elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits. Hum. Vaccines Immunother. 8 (2012), 1764–1768.
67. 67•• ••] Larocca, R.A., et al. Vaccine protection against Zika virus from Brazil. Nature 536 (2016), 474–478 This is the first article describing a vaccine against ZIKV tested in mice. Both PIV and DNA plasmid vaccine fully protected mice against a ZIKV challenge.
68. 68•• Abbink, P., et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science 353 (2016), 1129–1132 This article is a follow up of Ref. [67] and describes the effect of these vaccines in monkeys. All vaccines fully protected animals against a ZIKV challenge.
69. 69 Sapparapu, G., et al. Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Nature 540 (2016), 443–447.
70. + T cells during a primary ZIKV infection in mice.
71. 71 Dejnirattisai, W., et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with Zika virus. Nat. Immunol. 17 (2016), 1102–1108.
72. 72 Priyamvada, L., et al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), 7852–7857.
73. 73 Charles, A.S., Christofferson, R.C., Utility of a dengue-derived monoclonal antibody to enhance Zika infection in vitro. PLoS Curr., 8, 2016.
74. 74•• Bardina, S.V., et al. Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity. Science, 2017 This article demonstrates that preexisting flavivirus antibodies are cross-reactive to ZIKV and enhance disease severity in whole organisms.
75. 75•• Dowd, K.A., et al. Rapid development of a DNA vaccine for Zika virus. Science 354 (2016), 237–240 This article found that a DNA vaccine can induce protection in mice and nonhuman primates.
76. 76 Pardi, N., et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 543 (2017), 248–251.
77. 77 Richner, J.M., et al. Modified mRNA vaccines protect against Zika virus infection. Cell 168 (2017), 1114–1125.